Pediatric studies for off-patent cancer drugs
Executive Summary
The Pediatric Subcommittee of FDA's Oncologic Drugs Advisory Committee will consider the availability of safety and efficacy data on off-patent oncology drugs for the pediatric population and whether additional information is needed at an Oct. 9 meeting. Age-appropriate formulation changes to facilitate dosing of products used in the pediatric oncology setting will also be discussed. The meeting will be held at the Holiday Inn in Silver Spring, Md. beginning at 8 a.m...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.